7/30/2019 | CVLM | Array BioPharma holders may convert, put 2.625% notes due to merger
|
2/6/2018 | CV | Market Commentary: Convertibles trading volume light amid equity market volatility; Array, Lumentum gain
|
2/6/2018 | CV | Market Commentary: Morning Commentary: Convertibles trading volume light amid equity market volatility
|
12/22/2017 | CV | Market Commentary: Cobalt trading frenzy goes on; Array jumps up; WWE smacked down; EZCorp strengthens
|
12/4/2017 | CVLM | Array calls last $6.2 million 3% convertibles due 2020 for redemption
|
11/22/2017 | CV | Market Commentary: High trade volume for Intel continues; Everbridge, Square, Array make gains
|
11/21/2017 | CV | Market Commentary: Palo Alto jumps on earnings report, Array BioPharma’s new notes gain steam, Tesla active
|
11/20/2017 | CVLM | Array BioPharma avoids equity dilution with upsized exchange agreement
|
11/20/2017 | CVLM | Array to swap $19 million more 2020 convertibles for stock, new notes
|
11/20/2017 | CV | Market Commentary: Intel continues to dominate trading, Array BioPharma upsizes exchange agreement
|
11/16/2017 | CVLM | Array to swap $107 million of 2020 convertibles for stock, new notes
|
9/27/2016 | CV | Market Commentary: Array BioPharma surges again in active trade; Great Plains, Goldman Sachs BDC launch deals
|
9/27/2016 | CV | Market Commentary: Morning Commentary: Array BioPharma surges again in active trade; Priceline bonds slip
|
8/22/2016 | CV | Market Commentary: Biotech names eyed after Medivation takeout news; BioMarin convertibles add with shares
|
5/31/2016 | CV | Market Commentary: Health care in focus as sector lifts; Softbank mandatory exchangeable into Alibaba on tap
|
5/31/2016 | CV | Market Commentary: Morning Commentary: Health care in focus as sector lifts following Celator acquisition news
|
11/4/2015 | CV | Market Commentary: Tesla convertibles flat after earnings miss; Anthem adds on swap; FireEye contracts
|
11/4/2015 | CV | Market Commentary: Morning Commentary: Convertibles primary remains quiet; Tesla Motors adds after earnings miss
|
1/26/2015 | CV | Market Commentary: FXCM strengthens; Molycorp adds; Array up; convertibles mostly quiet ahead of Nor’easter
|
1/23/2015 | CV | Market Commentary: Priceline active; FXCM better despite lower shares; Array BioPharma surges on drug deal
|
6/7/2013 | CV | Array BioPharma greenshoe ups 3% convertibles deal to $132.25 million
|
6/6/2013 | CV | Market Commentary: Planned Jarden looks fair to rich; existing Jarden slips on swap; market seen quiet, weak
|
6/5/2013 | CV | Market Commentary: Array adds a point in busy debut; market weaker; DDR off 0.25 point; Prologis in 0.5 point
|
6/5/2013 | CV | New Issue: Array BioPharma sells upsized $115 million seven-year convertibles at 3%, up 32.5%
|
6/4/2013 | CV | Market Commentary: New Dominions trade around reoffered price and lower; planned Array note valuations eyed
|
6/3/2013 | CV | Array BioPharma to sell $100 million seven-year convertibles to yield 3%-3.5%, up 27.5%-32.5%
|
6/3/2013 | CV | Market Commentary: Dominion seen in gray near reoffer price; convertibles mostly quiet, better sellers seen
|
11/23/2011 | CVHYPF | Array BioPharma files $150 million shelf for stock and preferreds
|
11/7/2008 | CVHY | Array Biopharma files $150 million shelf registration
|
10/6/2006 | BTCV | Array Biopharma files $150 million stock, warrant shelf
|